Cobalis Corp.
PreHistin significantly reduces allergy symptoms in 714-patient phase III clinical trial
Published in FDA Law Weekly, November 24th, 2005
The study was the largest of its kind, according to Lyndon Mansfield, MD, Cobalis' senior medical advisor, and successfully concludes one of the most important milestones towards gaining FDA approval to market PreHistin in the U.S. as an over the counter (OTC) medication for preseasonal treatment of allergy symptoms.
The study demonstrated strong clinical and statistical significance that...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly
Source: FDA Law Weekly (2005-11-24)
More Articles from FDA Law Weekly
- Aethlon Medical, Inc.
CEO discusses Project BioShield legislation and treatment strategies for biological weapons - Alba Therapeutics Corp.
First human trial for AT-1001 completed; U.S. FDA grants fast-track designation - Allergy and Immunology Associates of Ann Arbor
Long-term budesonide inhalation well tolerated in children with asthma - AlphaVax
Vaccine maker reports $3.3M grant to develop smallpox vaccine - Alza Corp.
Letter issued from U.S. FDA on Dapoxetine application - Amarillo Biosciences, Inc.
Low dose oral interferon licensed to Global Kinetics for sale in three Asian countries - More from this issue of FDA Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
